Q-omics provides the consensus-scored ZNF532 profile across patient tissues and cancer cell-line models. ZNF532 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, ZNF532 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, ZNF532 RNA expression shows 20,631 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LIHC, HNSC, and THYM as cancer lineages where ZNF532 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF532 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF532 survival associations across molecular data types. ZNF532 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF532 RNA expression–survival associations across cancer types. High ZNF532 expression shows unfavorable associations in LIHC, LAML, BLCA, PAAD, COAD and MESO. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for ZNF532 RNA expression.
This table summarizes ZNF532 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF532. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF532 shows higher tumor expression in HNSC, KIRC, LIHC, LUAD, LUSC and CHOL. The HNSC box plot shows higher ZNF532 RNA expression in tumor versus normal tissue (log2 FC = +1.521, t-test p < 0.001).
This table shows molecular features associated with ZNF532 in patient tissues and cancer cell lines. In patient samples, ZNF532 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF532 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BONE.
